Day: November 30, 2020

BOSTON and JERUSALEM, Nov. 30, 2020 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its Board of Directors has appointed Spiros Jamas, Sc.D. to the role of Chief Executive Officer and a member of the Board of Directors effective January 4, 2021. Dr. Jamas will succeed Dr. Roger Garceau, who has been serving as interim CEO since August 2020. Dr. Garceau will continue to serve as a Director of Entera Bio.“This is an incredibly exciting time to join the talented team at Entera, with several near-term catalysts including multiple data readouts from the ongoing Phase 2 clinical trial of EB613 as well as numerous potential business development opportunities for our platform technology,” said Dr. Jamas. “I look forward to working with the...

MALVERN, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Chief Financial Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020.

JERSEY, Channel Islands, Nov. 30, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported preliminary EU field trial performance data for its MosaiQ Expanded Immunohematology (IH) Microarray. The data suggest that tests performed with Quotient’s Microarray are highly accurate.Expanded IH Microarray Preliminary PerformanceTo date in the EU field trial, over 4000 randomly selected human blood donor samples have been tested. The concordance data obtained through the study are as follows:The preliminary field trial data were obtained in testing laboratories using microarrays manufactured in Quotient’s ISO certified manufacturing facility in combination with the CE marked MosaiQ instrument.The Company plans to make a CE mark submission for the Expanded IH microarray...

DALLAS, Nov. 30, 2020 (GLOBE NEWSWIRE) — Triumph Bancorp, Inc. (the “Company”) (Nasdaq: TBK) today announced the Company’s Board of Directors declared a quarterly cash dividend of $17.81 per share on its 7.125% Series C Fixed-Rate Non-Cumulative Perpetual Preferred Stock, represented by depositary shares (NASDAQ: TBKCP), each representing a 1/40th interest in a share of preferred stock. Holders of depositary shares will receive $0.44525 per depositary share. The dividend is payable on December 30, 2020, to holders of record at the close of business on December 15, 2020.About TriumphTriumph Bancorp, Inc. (Nasdaq: TBK) is a financial holding company headquartered in Dallas, Texas.  Triumph offers a diversified line of community banking, national lending, and commercial finance products through its bank subsidiary, TBK Bank, SSB. www.triumphbancorp.com.Forward-Looking...

FLORHAM PARK, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has completed patient enrollment in PHALCON-EE, the Company’s pivotal Phase 3 clinical trial of vonoprazan for both the healing and maintenance of healing of erosive esophagitis (EE) as well as the relief of heartburn. Phathom exceeded the patient enrollment target of 1,000 patients. Phathom continues to expect topline results from the PHALCON-EE trial in the second half of 2021.PHALCON-EE is a randomized, double-blind, two-phase, multicenter Phase 3 trial that has enrolled over 1,000 patients with EE in the U.S. and Europe. The first phase of the trial is evaluating the efficacy...

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety and efficacy of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney condition that often leads to end-stage kidney disease (ESKD). Topline efficacy data from the interim 36-week proteinuria endpoint analysis are expected in the first quarter of 2021.“Many people living with FSGS are unable to delay progression to end-stage kidney disease and ultimately face transplant or dialysis,” said Noah Rosenberg, M.D., chief medical officer of Travere Therapeutics. “New treatment options are desperately needed. By completing enrollment in the DUPLEX Study, we have achieved the next milestone on our...

TEMPE, Ariz., Nov. 30, 2020 (GLOBE NEWSWIRE) — Wrap Technologies, Inc. (the “Company” or “WRAP”) (Nasdaq: WRTC), an innovator of modern policing solutions, announced today that Virginia Police Department in Minnesota captured a successful deployment of the BolaWrap® Remote Restraint device on bodycam earlier this month. WRAP will be releasing the bodycam footage tomorrow morning during a live webinar at 10amET on Zoom.During the webinar, WRAP executives will review the bodycam footage and display a recorded interview with Chief Nicole Young-Mattson of Virginia Police Department. To attend the webinar, please register here.The bodycam footage will be made public on WRAP’s YouTube channel following the webinar.WRAP on Facebook: https://www.facebook.com/wraptechnologies/WRAP on Twitter: https://twitter.com/wraptechincWRAP on LinkedIn:...

MATTOON, Ill., Nov. 30, 2020 (GLOBE NEWSWIRE) — Consolidated Communications (NASDAQ: CNSL) a leading broadband and business communications provider, today announced the launch of a new technology-focused educational grant program, Consolidated Connects, available to K-12 schools across its service area.As a leading fiber provider with a mission to turn technology into solutions and to connect people and enrich how they work and live, Consolidated’s new program encourages project-based learning and the use of innovative technologies.“Technology and broadband services play a critical role in everything we do today and for the future,” said Jennifer Spaude, senior vice president, Corporate Communications and Investor Relations at Consolidated Communications. “The Consolidated Connects Educational Grant Program will help ensure students...